Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Celyad Oncology SA

CYAD.BR ✓ COMPLIANT ☆ Track — members

Euronext Brussels · Healthcare · Biotechnology & Medical Research ·

Belgium Micro Cap Analyst: HOLD

Last Close

$0.30

▼ -4.03%

Market Cap $14.39M · Vol 2.06K

Key Metrics

P/E Ratio

19.60

FWD: N/A

Market Cap

$14.39M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

44.86

Momentum

Beta

0.92

vs Market

52W High

$0.76

60.48% below

52W Low

$0.19

62.01% above

Volume

2.06K

Avg 13.71K

P/B

3.12

Price-to-book

ROE

N/A

Return on equity

Free Float

34.30%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Celyad Oncology SA (CYAD.BR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CYAD.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.38%

-2.96%

-7.09%

-28.22%

YTD

+54.12%

-12.96%

-63.14%

-93.34%

Financials & Valuation

TTM · Annual

Total Revenue	$24.66K
Net Income	$974.83K
Revenue Growth (YoY)	-95.93%
Gross Margin	61.90%
Operating Margin	-13,928.57%
Net Profit Margin	3,952.38%
ROE	N/A
ROA · ROIC	11.67% · N/A

P/E Ratio	19.60
Forward P/E (FY1)	N/A
PEG Ratio	0.08
P/S	346.32
P/B	3.12
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	47.26M

Technical Indicators

50-Day SMA	$0.30
200-Day SMA	$0.31
RSI (14)	44.86
Beta	0.92
52-Week High	$0.76
52-Week Low	$0.19

Volume Today	2.06K
Avg Daily Volume (30D)	13.71K
Relative Volume	0.15x
Volatility (10D)	53.65
Volatility (30D)	62.22
Free Float	34.30%

Analyst Consensus

HOLD

Current Price $0.30

Mean Target N/A

52W Low$0.19 52W High$0.76

Current

Target

$0.19 $0.76

Current Analyst target

· 0 analysts

Identifiers

ExchangeEuronext Brussels

FIGIBBG001T539K9

ISINBE0974260896

CountryBelgium

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.82% RVMD Revolution Medicines Inc -1.29% ONC BeOne Medicines AG -1.89% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +3.62%

Company Profile

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).